Novo Nordisk’s sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 177.0B in 2022. Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates to DKK 74.8B. For the 2023 outlook, both sales and operating profit growth are expected to be 13-19% at CER. Sales and operating profit growth reported in Danish kroner are expected to be 4 and 5 percentage points lower than at CER, respectively. Lars Fruergaard Jorgensen, president and CEO, said: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. We continued to make progress on our Strategic aspirations and in 2023, we will continue our focus on strong commercial execution, expanding and progressing our innovative pipeline and investing significantly in the expansion of production capacity for current and future portfolio."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
- Novo Nordisk announces FDA approval of label update for Rybelsus
- California AG files suit against drugmakers, PBMs over insulin prices
- Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
- Novo Nordisk added to Analyst Focus List at JPMorgan